SCHEMBL15550992

SCHEMBL15550992

CCN(C(=O)c1ccccc1)c1nc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HPGD P15428 3/20 0.46
HTT P42858 2/20 0.46
PKM P14618 1/20 0.46
MAOB P27338 1/20 0.46
ADORA2A P29274 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15550310 0.91 LMNA (0.52) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL9162960 0.87 LMNA (0.60) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL15550324 0.86 LMNA (0.50) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL4888617 0.81 LMNA (0.56) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL11705405 0.78 RAB9A (0.49) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL1231980 0.78 CYP1A2 (0.50) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL11782333 0.76 ALDH1A1 (0.50) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL11429894 0.74 LMNA (0.48) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL6955715 0.74 LMNA (0.96) LMNACYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL28371143 0.74 LMNA (0.45) LMNACYP1A2CYP2D6CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA LMNA 3064/4885CYP1A2 1933/4885CYP2D6 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.